Unraveling the Complexity of Amyotrophic Lateral Sclerosis: Recent Advances from the Transgenic Mutant SOD1 Mice

Author(s): M. Peviani, I. Caron, C. Pizzasegola, F. Gensano, M. Tortarolo, C. Bendotti

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders

Volume 9 , Issue 4 , 2010

Become EABM
Become Reviewer
Call for Editor


Amyotrophic Lateral Sclerosis (ALS), which accounts for the majority of motor neuron disorders, is a progressive and fatal neurodegenerative disease leading to complete paralysis of skeletal muscles and premature death usually by respiratory failure. About 10% of all ALS cases are inherited, with the responsible genes having been identified in approximately 30% of these individuals. Mutations in the copper-zinc superoxide dismutase (SOD1) gene were the first to be recognized nearly twenty years ago, and since then different animal models, in particular transgenic rodents, have been developed. They replicate many of the clinical, neuropathological and molecular features of ALS patients and have contributed significantly to our understanding of the pathogenic mechanisms of this disease. Although results obtained so far with mutant SOD1 mice have not translated into effective therapies in ALS patients, these models still represent the only experimentally accessible system to study multiple aspects of disease pathogenesis and to provide proof-of-principle for the development of new therapeutic strategies. This review will examine the most recent discoveries obtained from these animal models in an attempt to elucidate the complex mechanisms of the disease. In particular it will focus on the contribution of multiple cell types in governing the disease development and progression.

Keywords: Amyotrophic lateral sclerosis, motor neuron, transgenic mouse models, SOD1

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [491 - 503]
Pages: 13
DOI: 10.2174/187152710791556096
Price: $65

Article Metrics

PDF: 15